OBSV

AcronymDefinition
OBSVOlympic Broadcasting Services Vancouver (Canada)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol 'OBSV' and on the SIX Swiss Exchange where it is trading under the ticker symbol 'OBSN'.
Significant differences were observed between the back-calculation methods (BC-all, BC-last) and the adjusted and observed methods (Adj-cat, Adj-frm, Obsv), and no significant differences were found between the two back-calculation methods for both species.
A clear pattern emerged that revealed large differences between the back-calculation (BC-all, BC-last) methods and the observed and adjusted methods (Obsv, Adj-cat, Adj-frm) for both species of mackerel.
"As in Beijing 2008, during the Vancouver 2010 Olympic Winter Games everything will be broadcast from the venues in High Definition," said Manolo Romero, OBSV's CEO.
* ObsEva (NASDAQ: OBSV) shares set a new yearly low of $8.44 this morning.
Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids.
Release date- 07082019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the closing of a $75 million senior secured credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies.
* ObsEva (NASDAQ: OBSV) shares made a new 52-week low of $8.53 on Monday.
Release date- 05082019 - Geneva - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019.
Obseva SA (NASDAQ: OBSV) said an independent data monitoring committee, or IDMC, that completed the unblinded review of data from the first 30 subjects randomized in Part B of the PROLONG trial in preterm labor with PGF2a receptor antagonist OBE022 recommended continuation of the trial without modification.
Release date- 26072019 - Geneva - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the Independent Data Monitoring Committee (IDMC) has completed the unblinded review of data from the first 30 subjects randomized in Part B of the PROLONG trial in preterm labor with PGF2a receptor antagonist OBE022.